SUN PHARMACEUTICAL INDUSTRIES Financial Statement Analysis
|
||
|
The Revenues of SUN PHARMACEUTICAL INDUSTRIES have increased by 10.51% YoY .
The Earnings Per Share (EPS) of SUN PHARMACEUTICAL INDUSTRIES has increased by 13.00 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
SUN PHARMACEUTICAL INDUSTRIES Last 5 Annual Financial Results
[BOM: 524715|NSE : SUNPHARMA]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹48,497 Cr | ₹43,886 Cr | ₹38,654 Cr | ₹33,498 Cr | ₹32,838 Cr |
| Expenses | ₹35,748 Cr | ₹32,298 Cr | ₹28,773 Cr | ₹25,030 Cr | ₹25,863 Cr |
| Operating Profit (Excl OI) | ₹12,749 Cr | ₹11,588 Cr | ₹9,882 Cr | ₹8,468 Cr | ₹6,974 Cr |
| Other Income | ₹1,628 Cr | ₹694 Cr | ₹1,437 Cr | ₹859 Cr | ₹652 Cr |
| Interest | ₹238 Cr | ₹172 Cr | ₹127 Cr | ₹141 Cr | ₹303 Cr |
| Depreciation | ₹2,557 Cr | ₹2,529 Cr | ₹2,144 Cr | ₹2,080 Cr | ₹2,053 Cr |
| Profit Before Tax | ₹11,088 Cr | ₹9,408 Cr | ₹4,481 Cr | ₹2,799 Cr | ₹5,010 Cr |
| Profit After Tax | ₹9,648 Cr | ₹8,561 Cr | ₹3,406 Cr | ₹2,285 Cr | ₹4,187 Cr |
| Consolidated Net Profit | ₹9,576 Cr | ₹8,474 Cr | ₹3,273 Cr | ₹2,904 Cr | ₹3,765 Cr |
| Earnings Per Share (Rs) | ₹39.91 | ₹35.32 | ₹13.64 | ₹12.10 | ₹15.69 |
| PAT Margin (%) | 19.89 | 19.51 | 5.07 | 3.72 | 7.05 |
| ROE(%) | 16.13 | 16.46 | 7.21 | 4.98 | 9.66 |
| ROCE(%) | 17.60 | 17.24 | 9.28 | 5.66 | 10.07 |
| Total Debt/Equity(x) | 0.04 | 0.11 | 0.02 | 0.08 | 0.18 |
Key Financials |
||
| Market Cap | : | ₹ 418,929.8 Cr |
| Revenue (TTM) | : | ₹ 50,307.7 Cr |
| Net Profit(TTM) | : | ₹ 11,136.5 Cr |
| EPS (TTM) | : | ₹ 46.4 |
| P/E (TTM) | : | 37.6 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| SUN PHARMACEUTICAL INDUSTRIES | -5.8% | -3.2% | 35.1% |
| CIPLA | -3.9% | -0.5% | 13.9% |
| DR REDDYS LABORATORIES | -1.2% | 7.1% | 17.8% |
| ZYDUS LIFESCIENCES | -2.7% | -0.1% | 40.9% |
| DIVIS LABORATORIES | -2.8% | -3.6% | 44.7% |
| MANKIND PHARMA | -11.2% | -2.3% | 33.6% |
| TORRENT PHARMACEUTICALS | -4.8% | -2.7% | 40.1% |
| LUPIN | -8.6% | 1.8% | 56.9% |
| AUROBINDO PHARMA | -10.4% | -4.4% | 7.2% |
SUN PHARMACEUTICAL INDUSTRIES Revenues
[BOM: 524715|NSE : SUNPHARMA]
| Y-o-Y | 10.51 % |
| 5 Yr CAGR | 10.24 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹48,497 Cr | 10.51 | |
| Mar2023 | ₹43,886 Cr | 13.53 | |
| Mar2022 | ₹38,654 Cr | 15.39 | |
| Mar2021 | ₹33,498 Cr | 2.01 | |
| Mar2020 | ₹32,838 Cr | - | |
SUN PHARMACEUTICAL INDUSTRIES Operating Profit
[BOM: 524715|NSE : SUNPHARMA]
| Y-o-Y | 10.02 % |
| 5 Yr CAGR | 16.28 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹12,749 Cr | 10.02 | |
| Mar2023 | ₹11,588 Cr | 17.26 | |
| Mar2022 | ₹9,882 Cr | 16.70 | |
| Mar2021 | ₹8,468 Cr | 21.42 | |
| Mar2020 | ₹6,974 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -0.42 % |
| 5 Yr CAGR | 5.48 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 26.29% | -0.42 | |
| Mar2023 | 26.4% | 3.29 | |
| Mar2022 | 25.56% | 1.11 | |
| Mar2021 | 25.28% | 19.02 | |
| Mar2020 | 21.24% | - | |
SUN PHARMACEUTICAL INDUSTRIES Profit After Tax
[BOM: 524715|NSE : SUNPHARMA]
| Y-o-Y | 13.01 % |
| 5 Yr CAGR | 26.29 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹9,576 Cr | 13.01 | |
| Mar2023 | ₹8,474 Cr | 158.91 | |
| Mar2022 | ₹3,273 Cr | 12.70 | |
| Mar2021 | ₹2,904 Cr | -22.87 | |
| Mar2020 | ₹3,765 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 1.95 % |
| 5 Yr CAGR | 29.60 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 19.89 % | 1.95 | |
| Mar2023 | 19.51 % | 284.81 | |
| Mar2022 | 5.07 % | 36.29 | |
| Mar2021 | 3.72 % | -47.23 | |
| Mar2020 | 7.05 % | - | |
SUN PHARMACEUTICAL INDUSTRIES Earnings Per Share (EPS)
[BOM: 524715|NSE : SUNPHARMA]
| Y-o-Y | 13.00 % |
| 5 Yr CAGR | 26.29 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹40 | 13.00 | |
| Mar2023 | ₹35 | 158.94 | |
| Mar2022 | ₹14 | 12.73 | |
| Mar2021 | ₹12 | -22.88 | |
| Mar2020 | ₹16 | - | |
SUN PHARMACEUTICAL INDUSTRIES Return on Capital Employed (ROCE)
[BOM: 524715|NSE : SUNPHARMA]
| Y-o-Y | 2.09 % |
| 5 Yr CAGR | 14.98 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 17.6% | 2.09 | |
| Mar2023 | 17.24% | 85.78 | |
| Mar2022 | 9.28% | 63.96 | |
| Mar2021 | 5.66% | -43.79 | |
| Mar2020 | 10.07% | - | |
SUN PHARMACEUTICAL INDUSTRIES Share Price vs Sensex
| Current Share Price | : | ₹1,746.1 |
| Current MarketCap | : | ₹ 418,929.8 Cr |
| Updated EOD on | : | Jan 13,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUN PHARMACEUTICAL INDUSTRIES | -5.8% |
-3.2% |
35.1% |
| SENSEX | -2.1% |
-6.4% |
7% |
SUN PHARMACEUTICAL INDUSTRIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE CARBONEX | 1.5% | 1.4% | 34.5% |
| S&P BSE GREENEX | 0.9% | 1.7% | 52.5% |
| S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
| S&P BSE SENSEX | -2.1% | -6.4% | 7% |
| S&P BSE LOW VOLATILITY | -2.2% | -4.3% | 8.7% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY GROWTH SECTOR 15 | 1.2% | 11.6% | 9.1% |
| NIFTY QUALITY LOW-VOLATILTY 30 | -1.4% | -4.3% | 8.3% |
| NIFTY100 LOW VOLATILITY 30 | -1.4% | -3.4% | 11.4% |
| NIFTY ALPHA QTY VAL LOW-VOL 30 | -2.2% | -7.2% | 16% |
| NIFTY 50 | -2.2% | -6.3% | 7.3% |
You may also like the below Video Courses
FAQ about SUN PHARMACEUTICAL INDUSTRIES Financials
How the annual revenues of SUN PHARMACEUTICAL INDUSTRIES have changed ?
The Revenues of SUN PHARMACEUTICAL INDUSTRIES have increased by 10.51% YoY .
How the Earnings per Share (EPS) of SUN PHARMACEUTICAL INDUSTRIES have changed?
The Earnings Per Share (EPS) of SUN PHARMACEUTICAL INDUSTRIES has increased by 13.00 % YoY .
Check out Intrinsic Value of Peers of SUN PHARMACEUTICAL INDUSTRIES
Compare Stock Analytics of Peers of SUN PHARMACEUTICAL INDUSTRIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
